Almi­rall part­ners up with Sim­cere in po­ten­tial $500M+ deal — with plans to take IL-2 can­di­date glob­al

A Chi­nese phar­ma is look­ing to go in­ter­na­tion­al with one of its pre­clin­i­cal can­di­dates, and it’s team­ing up with a Span­ish com­pa­ny in a new pact po­ten­tial­ly worth half a bil­lion dol­lars to do just that.

Sim­cere and Almi­rall an­nounced Thurs­day that the two com­pa­nies had reached a deal for Sim­cere’s IL-2 mu­tant fu­sion pro­tein drug can­di­date, called SIM0278. Ac­cord­ing to a state­ment, Almi­rall gets an ex­clu­sive right to de­vel­op and com­mer­cial­ize the drug can­di­date in all in­di­ca­tions and mar­kets out­side of Chi­na, Hong Kong, Tai­wan and Macau.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER